BRCA1 and neoplasm: Its capacity to resolve exon-level CNVs in highly heterogeneous samples makes it particularly suitable for APC and other malignancies characterized by high intratumoral heterogeneity, where only a small fraction of tumor cells may harbor BRCA1/2 alterations [18,20].